Phaseline

Targets › CEBPB

CEBPB (CCAAT/enhancer-binding protein beta): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.

Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. Also plays a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. (UniProt, P17676)

Open in Phaseline: the race on CEBPB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
XfibraXFB19
C/EBPβ Thr266 phosphorylation inhibitor targeting NLRP3 inflammasome activation
CEBPBPhase 1Focus of the Study: Safety of XFB19Dec 2026

Conditions

Focus of the Study: Safety of XFB19 (1)

Modalities

small molecule (1)

Companies

Xfibra (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.